09:28 AM EDT, 04/18/2024 (MT Newswires) -- Evotec (EVO) and Variant Bio said Thursday they have signed a collaboration deal to work on a treatment for diseases caused by fibrosis.

The partnership will use Variant Bio's genomic discovery know-how and VB-Inference platform and Evotec's expertise in antifibrotic drug discovery, the companies said.

Also, the project may assess unrelated nephrology targets based on data from Evotec's molecular patient database, the companies said.

Evotec will get research funding and may also get pre-clinical and clinical milestones and/or royalties, which are linked to the success of the project.